Amber L. Beitelshees
University of Maryland, Baltimore
159 Papers
970 Citations
Amber L. Beitelshees is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Medicine & Atenolol. The author has an hindex of 36, co-authored 133 publications. Previous affiliations of Amber L. Beitelshees include Cleveland Clinic & University of Maryland University College.
Chat about Author
Papers
Adrenergic-Pathway Gene Variants Influence Beta-Blocker–Related Outcomes After Acute Coronary Syndrome in a Race-Specific Manner
Sharon Cresci,Gerald W. Dorn,Philip G. Jones,Amber L. Beitelshees,Allie Y. Li,Petra A. Lenzini,Michael A. Province,John A. Spertus,David E. Lanfear +8 more
TL;DR: Adrenergic pathway polymorphisms are associated with mortality in ACS patients receiving BB in a race-specific manner, and the mechanism by which different genes impact post-ACS mortality differently in Caucasians and African Americans might illuminate opportunities to improve BB therapy in these groups.
43
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Nita A. Limdi,Larisa H. Cavallari,Craig R. Lee,William B. Hillegass,Ann M. Holmes,Todd C. Skaar,Maria Pisu,Chrisly Dillon,Amber L. Beitelshees,Philip E. Empey,Julio D. Duarte,Diaby,Yan Gong,Julie A. Johnson,John A. Graves,Shawn P. Garbett,Zilu Zhou,Josh F. Peterson +17 more
TL;DR: YP2C19 genotype-guided antiplatelet prescribing is cost-effective compared with either universal clopidogrel or universal ticagrelor using real-world implementation data and nonguided de-escalation may be viable strategies, needing further evaluation.
42
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Craig R. Lee,Cameron D. Thomas,Amber L. Beitelshees,Sony Tuteja,Philip E. Empey,James C. Lee,Nita A. Limdi,Julio D. Duarte,Todd C. Skaar,Yiqing Chen,Kelsey J. Cook,James C. Coons,Chrisly Dillon,Francesco Franchi,Jay Giri,Yan Gong,Rolf P. Kreutz,Caitrin W. McDonough,James M. Stevenson,Karen E. Weck,Dominick J. Angiolillo,Julie A. Johnson,George A. Stouffer,Larisa H. Cavallari +23 more
TL;DR: In a real‐world setting of genotype‐guided antiplatelet therapy, the CYP2C19*17 allele did not significantly impact post‐PCI prescribing decisions or clinical outcomes, suggesting the CYp2C 19 *1/*17 and *17/*17 genotypes have limited clinical utility to guide antiplatelets therapy after PCI.
41
Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations
Sachiko Yoneyama,Yiran Guo,Yiran Guo,Matthew B. Lanktree,Michael R. Barnes,Michael R. Barnes,Clara C. Elbers,Konrad J. Karczewski,Sandosh Padmanabhan,Florianne Bauer,Jens Baumert,Amber L. Beitelshees,Gerald S. Berenson,Jolanda M. A. Boer,Gregory L. Burke,Brian E. Cade,Wei Chen,Rhonda M. Cooper-DeHoff,Tom R. Gaunt,Christian Gieger,Yan Gong,Mathias Gorski,Nancy L. Heard-Costa,Toby Johnson,Michael J. LaMonte,Caitrin W. McDonough,Keri L. Monda,Keri L. Monda,N. Charlotte Onland-Moret,Christopher P. Nelson,Christopher P. Nelson,Jeffrey R. O'Connell,Jose M. Ordovas,Inga Peter,Annette Peters,Jonathan A. Shaffer,Haiqinq Shen,Erin N. Smith,Liz Speilotes,Liz Speilotes,Liz Speilotes,Fridtjof Thomas,Barbara Thorand,W. M. Monique Verschuren,Sonia S. Anand,Sonia S. Anand,Anna F. Dominiczak,Karina W. Davidson,Robert A. Hegele,Iris M. Heid,Marten H. Hofker,Gordon S. Huggins,Thomas Illig,Julie A. Johnson,Susan Kirkland,Wolfgang König,Taimour Y. Langaee,Jeanne M. McCaffery,Jeanne M. McCaffery,Olle Melander,Braxton D. Mitchell,Patricia B. Munroe,Sarah S. Murray,George J. Papanicolaou,Susan Redline,Muredach P. Reilly,Nilesh J. Samani,Nilesh J. Samani,Nicholas J. Schork,Nicholas J. Schork,Yvonne T. van der Schouw,Daichi Shimbo,Alan R. Shuldiner,Alan R. Shuldiner,Martin D. Tobin,Cisca Wijmenga,Salim Yusuf,Salim Yusuf,Hakon Hakonarson,Leslie A. Lange,Ellen W. Demerath,Caroline S. Fox,Kari E. North,Alexander P. Reiner,Brendan J. Keating,Kira C. Taylor +85 more
TL;DR: Functional analysis using ENCODE and eQTL databases revealed that several of these loci are in regulatory regions or regions with differential expression in adipose tissue, supporting an already established sexual dimorphism of central adiposity-related genetic variants.
Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients
Laura B. Ramsey,Laura B. Ramsey,Henry H. Ong,Jonathan S. Schildcrout,Yaping Shi,Leigh Anne Tang,J. Kevin Hicks,Nihal El Rouby,Nihal El Rouby,Larisa H. Cavallari,Sony Tuteja,Christina L. Aquilante,Amber L. Beitelshees,Daniel L. Lemkin,Kathryn V. Blake,Helen Williams,James J. Cimino,Brittney H. Davis,Nita A. Limdi,Philip E. Empey,Christopher M. Horvat,David P. Kao,Gloria Lipori,Marc B. Rosenman,Marc B. Rosenman,Todd C. Skaar,Evgenia Teal,Almut G. Winterstein,Aniwaa Owusu Obeng,Daria Salyakina,Apeksha Gupta,Joshua B. Gruber,Jennifer McCafferty-Fernandez,Jeffrey R. Bishop,Zach Rivers,Ashley Benner,Bani Tamraz,Janel Long-Boyle,Josh F. Peterson,Sara L. Van Driest +39 more
- 01 Dec 2020
TL;DR: This cross-sectional study assesses potential opportunities for genotype-guided prescribing in pediatric populations among multiple health systems by examining the prevalence of prescriptions for each drug with the highest level of evidence and estimating the likelihood of potentially actionable prescribing decisions.